ERBB2 and invasive breast carcinoma: ERBB2 status is a determinant for stratifying invasive breast cancer concerning ERBB2-directed targeted therapy (Ahmed et al., 2015; Goutsouliak et al., 2020; Oh and Bang, 2020), including ERBB2-targeted monoclonal antibodies and small-molecule tyrosine kinase inhibitors such as lapatinib (Xia et al., 2005).